0001415889-23-016532.txt : 20231215 0001415889-23-016532.hdr.sgml : 20231215 20231215164021 ACCESSION NUMBER: 0001415889-23-016532 CONFORMED SUBMISSION TYPE: 4 PUBLIC DOCUMENT COUNT: 1 CONFORMED PERIOD OF REPORT: 20231215 FILED AS OF DATE: 20231215 DATE AS OF CHANGE: 20231215 REPORTING-OWNER: OWNER DATA: COMPANY CONFORMED NAME: DIXON WENDY L CENTRAL INDEX KEY: 0001202283 FILING VALUES: FORM TYPE: 4 SEC ACT: 1934 Act SEC FILE NUMBER: 001-39200 FILM NUMBER: 231490960 ISSUER: COMPANY DATA: COMPANY CONFORMED NAME: Black Diamond Therapeutics, Inc. CENTRAL INDEX KEY: 0001701541 STANDARD INDUSTRIAL CLASSIFICATION: BIOLOGICAL PRODUCTS (NO DIAGNOSTIC SUBSTANCES) [2836] IRS NUMBER: 000000000 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 BUSINESS ADDRESS: STREET 1: ONE MAIN STREET, 14TH FLOOR CITY: CAMBRIDGE STATE: MA ZIP: 02142 BUSINESS PHONE: 617-417-5868 MAIL ADDRESS: STREET 1: ONE MAIN STREET, 14TH FLOOR CITY: CAMBRIDGE STATE: MA ZIP: 02142 FORMER COMPANY: FORMER CONFORMED NAME: Aset Therapeutics, Inc. DATE OF NAME CHANGE: 20170321 4 1 form4-12152023_091215.xml X0508 4 2023-12-15 0001701541 Black Diamond Therapeutics, Inc. BDTX 0001202283 DIXON WENDY L C/O BLACK DIAMOND THERAPEUTICS, INC. ONE MAIN STREET, 14TH FLOOR CAMBRIDGE MA 02142 true false false false 0 Common Stock 2023-12-15 4 A 0 4043 2.73 A 34801 D These shares were issued in accordance with the Issuer's Fourth Amended and Restated Non-Employee Director Compensation Policy, pursuant to which the Reporting Person elected to receive shares of the Issuer's common stock in lieu of cash compensation for annual services as a non-employee director of the Issuer. The price reported in Column 4 is based upon the closing market price of the Issuer's common stock on December 14, 2023. /s/ Brent Hatzis-Schoch, Attorney-in-Fact 2023-12-15